中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

15 records (took 0.018 seconds)

    PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE
    5.
    发明申请
    PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE 失效
    吡咯并[3,2-d]吡嗪PI3K DELTA抑制剂化合物及其使用方法

    公开(公告)号：US20130225557A1

    公开(公告)日：2013-08-29

    申请号：US13854635

    申请日：2013-04-01

    Applicant: Genentech, Inc.

    Inventor： Georgette Castanedo ,  Bryan Chan ,  Matthew C. Lucas ,  Brian Safina ,  Daniel P. Sutherlin ,  Zachary Sweeney

    IPC: C07D471/04 ,  C07D491/107

    CPC classification number: C07D471/04 ,  C07D491/107

    Abstract: Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

    Abstract translation: 式I化合物，包括立体异构体，几何异构体，互变异构体，代谢物及其药学上可接受的盐，可用于抑制PI3K的δ同种型，以及用于治疗由脂质激酶如炎症，免疫学障碍和癌症介导的病症。 公开了使用式I化合物在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。

    PYRAZOLOPYRIDINE COMPOUNDS
    10.
    发明申请
    PYRAZOLOPYRIDINE COMPOUNDS 审中-公开
    吡唑并吡啶化合物

    公开(公告)号：US20140288043A1

    公开(公告)日：2014-09-25

    申请号：US13847409

    申请日：2013-03-19

    Applicant: Genentech, Inc.

    Inventor： Bryan Chan ,  Anthony Estrada ,  Daniel Shore ,  Zachary Sweeney

    IPC: C07D471/04 ,  C07D519/00

    CPC classification number: C07D471/04 ,  C07D519/00

    Abstract: A first aspect of the invention relates to a compound of formula (1A) or (1B), or a pharmaceutically acceptable salt thereof, Wherein R1 is a group selected from alkyl, monocyclic heterocycloalkyl, bicyclic heterocycloalkyl and cycloalkyl, each of which is optionally substituted, and wherein X1, X2, X3 and X4 are as defined herein. Further aspects relate to pharmaceutical compositions, therapeutic uses and process for preparing compounds of formula (1A) and (1B).

    Abstract translation: 本发明的第一方面涉及式（1A）或（1B）化合物或其药学上可接受的盐，其中R1是选自烷基，单环杂环烷基，双环杂环烷基和环烷基的基团，其各自任选被取代 ，并且其中X1，X2，X3和X4如本文所定义。 其它方面涉及药物组合物，治疗用途和制备式（1A）和（1B）化合物的方法。

Patent Agency Ranking